FDA DRUG GUIDELINES
![21 CFR Part 314 Guidelines for FDA Approval to Market a New Drug](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhYBUH8T2CaWjIIGVOGAZI1ZmjJxb8vjqnVeWnykQzYKRjkubNwIHbAlCcJN2VNtoFh4JCUr_0Iv5h2i4vI8EOpRQ8b05I_Ud8WadRQ3WHXt-pknJ7R0WzvYOxDwoTB06gf3ckKkbAZNovnvW5lsrFxTKD1UUTPtf-fa99WXJ8NcF03o_Q4TT7xNvUSbVo/w72-h72-p-k-no-nu/21%20CFR%20Part%20314.jpg)
FDA DRUG GUIDELINES
Sathyanarayana M.Sc.
July 03, 2022
21 CFR Part 314 Guidelines for FDA Approval to Market a New Drug
![Sathyanarayana M.Sc.](http://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjpEGiHgao13-NNSAw3snTKCiEIdXQk__fZFY4TBHQlFqmxBPNMiEkat4BC0LsUcOUeYx0q6ayORly_2NFM_7zjfJzDvz_R7bJ_ZTz51qyjZrc2DYH3_wX8Xfup2KXRdLw/w70/Logo.png)
![21 CFR Part 212 CGMP Guidelines for Positron Emission Tomography Drugs](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjzlLaxYIRzHXunifZvuv2UE-BS6e3SDyFlOwQV3vBFUvcBV1tk79JgCOKK6SybPBYKxdbcf0khqvUI4HzeDCj9yzSqB7ONsq1g77YMf-ynVyPoyOvQPy_7KWJwFVE4DlZ2ryCskm6zbg3hyphenhyphend7sVad62_MMZ1tV681BGuZaQbMtcVs5qqpJ8cH7uu_tj-k/w72-h72-p-k-no-nu/21%20CFR%20Part%20212.jpg)
FDA DRUG GUIDELINES
Sathyanarayana M.Sc.
July 03, 2022
21 CFR Part 212 CGMP Guidelines for Positron Emission Tomography Drugs
![Sathyanarayana M.Sc.](http://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjpEGiHgao13-NNSAw3snTKCiEIdXQk__fZFY4TBHQlFqmxBPNMiEkat4BC0LsUcOUeYx0q6ayORly_2NFM_7zjfJzDvz_R7bJ_ZTz51qyjZrc2DYH3_wX8Xfup2KXRdLw/w70/Logo.png)
![Data Integrity and Compliance with Drug CGMP](https://4.bp.blogspot.com/-O3EpVMWcoKw/WxY6-6I4--I/AAAAAAAAB2s/KzC0FqUQtkMdw7VzT6oOR_8vbZO6EJc-ACK4BGAYYCw/w680/nth.png)
FDA DRUG GUIDELINES
Sathyanarayana M.Sc.
December 12, 2020
Data Integrity and Compliance with Drug CGMP
![Sathyanarayana M.Sc.](http://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjpEGiHgao13-NNSAw3snTKCiEIdXQk__fZFY4TBHQlFqmxBPNMiEkat4BC0LsUcOUeYx0q6ayORly_2NFM_7zjfJzDvz_R7bJ_ZTz51qyjZrc2DYH3_wX8Xfup2KXRdLw/w70/Logo.png)
![FDA Approaches to GMP Inspection Guidelines](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgRZs9mU2KW0UNYZl_dkg2lULaIZnKNtZF4lIOS7Qx0zssXRPw0m2Zr0l2yIB2MzNNK8jZzoVsXV-jvEA6UnMsq1s4Ep68W3pX2zIFfSOh00fBFeU8-GbvPUMILn5j0QSI67EJIMGcc2Sw/w72-h72-p-k-no-nu/Drug-Inspection-Overview-01.jpg)
FDA DRUG GUIDELINES
Sathyanarayana M.Sc.
December 12, 2020
FDA Approaches to GMP Inspection Guidelines
![Sathyanarayana M.Sc.](http://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjpEGiHgao13-NNSAw3snTKCiEIdXQk__fZFY4TBHQlFqmxBPNMiEkat4BC0LsUcOUeYx0q6ayORly_2NFM_7zjfJzDvz_R7bJ_ZTz51qyjZrc2DYH3_wX8Xfup2KXRdLw/w70/Logo.png)